1. Clinical Trial Evidence (Castro-Marrero et al., 2015 & 2021)
In a series of landmark randomized, double-blind, placebo-controlled trials published by Spanish neuro-immunologist Dr. Jesús Castro-Marrero (PMID: 34444851, PMID: 25386884), the synergy of CoQ10 plus NADH was evaluated in 207 ME/CFS patients over 12 weeks:
- Significant ATP Elevation: Peripheral blood mononuclear cell (PBMC) ATP levels increased significantly compared to placebo.
- Cognitive Fatigue Reduction: Patients exhibited statistically significant improvements in processing speed and mental fatigue on the FIS-40 scale.
- Autonomic Cardiac Recovery: Post-exercise heart rate recovery was significantly accelerated, indicating improved parasympathetic reactivation.
2. Form Matters: Ubiquinol vs. Ubiquinone
In healthy young individuals, oxidized ubiquinone is efficiently converted in the gut wall and liver into reduced ubiquinol. In ME/CFS, extensive lipid peroxidation and glutathione depletion impair endogenous reducing enzymes.
Clinical Guideline: Patients should select Ubiquinol (Kaneka QH patent or emulsified lipid softgels), which achieves plasma concentrations up to 8 times higher than standard ubiquinone crystals.
Peer-Reviewed References
- Castro-Marrero J, et al. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide (NADH) supplementation on maximum heart rate and fatigue in ME/CFS: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2016;35(4):788-797. PMID: 25386884.
- Castro-Marrero J, et al. Does Oral Coenzyme Q10 Plus NADH Supplementation Improve Fatigue and Biochemical Parameters in ME/CFS? Antioxidants. 2021;10(8):1258. PMID: 34444851.
- Morris G, et al. The emerging role of Coenzyme Q10 in the management of ME/CFS. Mol Neurobiol. 2013;48(3):883-903. PMID: 23661416.